Nivolumab 360mg for Kidney Cancer

"According to the website, this study is not presently looking for candidates as it has already completed recruitment. The original posting was on April 24th, 2017 with the most recent update being from October 25th, 2022. Although this trial is no longer active, there are 3461 other studies that are ongoing and actively recruiting patients."

"Nivolumab, at a standard dosage of 240 mg, was first studied in 2009 Texas Children's Hospital. To date, there have been 360 completed clinical trials and presently there are 796 active ones; Chicago, Illinois has a large number of these ongoing studies."

"Nivolumab 240mg can be used to treat patients that have undergone anti-angiogenic therapy, have malignant neoplasms, and/or unresectable melanoma."

"Nivolumab 240 mg is considered to be a safe medication, as there is some clinical data supporting its safety. However, because this is only a Phase 2 trial, the efficacy of Nivolumab has not been conclusively determined."

"Unfortunately, this particular trial is no longer recruiting patients. It was initially posted on April 24th, 2017 and last edited on October 25th, 2022. However, there are presently 2665 trials actively searching for patients with carcinoma and 796 trials for Nivolumab 240 mg that are enrolling patients."

"There are 13 clinical trial sites for this study, which is recruiting patients. The locations include: Northwestern University Feinberg Schooll Of Medicine (Chicago, Illinois), University of Illinois Cancer Center (Washington, District of Columbia), Georgetown University (Atlanta, Georgia), and 10 other centres."